[Baiji 06160.HK will resolutely defend patent infringement allegations initiated by Baiji] as of press time, Baiji China (06160.HK) rose 7.14%. According to the news, in the early morning of June 16, Baiji China posted that the company was concerned about Pharmacyclics LLC's complaint against Baiji China, claiming that Zabutinib, a tumor drug from Baiji China, infringed a patent granted by Pharmacyclics on June 13, 2023. Baiji China said its research and development was original and would resolutely defend all such patent infringement allegations.